• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
APLS

APLS

Apellis Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD41.03

+0.00 (+0.00%)

Company Profile

CEO

Cedric Francois

IPO Date

2017-11-09

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$41.05

Prev. Close

$41.03

Day Low

$41.03

Day High

$41.05

52W Low

$16.61

52W High

$41.14

Market Cap

$5.25B

Volume

28.64M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

30.5%

Avg Negative

22.4%

Avg Neutral

47.3%

News Feed

Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates

Zacks Investment Research·8/10/2021·↓ negative

Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/10/2021·↓ negative

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

Recap: Apellis Pharmaceuticals Q2 Earnings

Benzinga·8/9/2021·↓ negative

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

GlobeNewsWire·7/26/2021·↓ negative

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

GlobeNewsWire·7/7/2021·↑ positive

Apellis (APLS) Up on Tie-up With Beam for Novel Therapies

Zacks Investment Research·7/2/2021·↑ positive

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders

Benzinga·7/1/2021·↑ positive

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

GlobeNewsWire·6/30/2021·↑ positive

Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

Zacks Investment Research·5/26/2021·↑ positive